Haemophilia Scotland has received an update from Roche regarding the Hemlibra supply amid coronavirus.
The statement is below:
“The World Health Organization (WHO) has declared the 2019-nCoV (novel coronavirus) outbreak a global pandemic. We extend our heartfelt sympathies to everyone who has lost loved ones, to patients and healthcare professionals battling this devastating outbreak.
With multiple countries implementing measures to slow the spread of the virus, based on the current situation, we wanted to provide an update to the community that Hemlibra supply continues to be stable for the foreseeable future.
We understand the interest in Hemlibra for people with haemophilia A and are committed to ensuring adequate supply. We are actively assessing and managing the situation on a daily basis, and have not identified any critical components that would impact our ability to supply Hemlibra in the future, based on current demand forecasts.
Our global manufacturing network has robust plans for dealing with the impact of potential health and other global crises. All manufacturing sites have site-specific plans in place with the goal of avoiding interruptions of product manufacturing, packaging or delivery for all of Roche’s medicines, including Hemlibra. We are also engaged with all of our key suppliers
to mitigate any potential impact to our supply chain.
We are continually taking proactive measures in collaboration with our logistics service providers to ensure the delivery of products to and from affected countries and regions remains stable. Should we become aware of any change to the supply or availability of Hemlibra at any point, we will inform the haemophilia community immediately.
8 April